{"entity":{"id":"nct05055908","kind":"trial","name":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors","aka":["BECOME"],"tldr":"A phase 3 trial of pemetrexed and pembrolizumab in lung cancer, run by Hunan Province Tumor Hospital, now recruiting.","summary":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors is a phase 3, interventional study registered as NCT05055908 by Hunan Province Tumor Hospital, with a registry enrolment figure of 12000 participants, started 2021-10-01 and due to reach its primary completion in 2025-07-01. Interventions recorded: Pemetrexed plus Pembrolizumab; Pembrolizumab; Pemetrexed. Conditions listed: Lung Cancer. Primary outcome: Correlation between Adverse events (AEs) and gene profile. Lung eligibility wording from the registry: \"Histologically or cytologically confirmed lung cancer\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05055908","url":"https://clinicaltrials.gov/study/NCT05055908"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["pemetrexed","pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05055908","phase":"3","setting":"Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy","sponsor":"Hunan Province Tumor Hospital","enrolled":12000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05055908/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}